SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase.
|Solubility (25°C)||DMSO 62.5 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Yaru Xue, et al. Gigantol ameliorates CCl 4-induced liver injury via preventing activation of JNK/cPLA2/12-LOX inflammatory pathway
 Sehwan Jang, et al. Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury
 Sehwan Jang, et al. Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK
 C Augustine, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro
|Related JNK Products|
CC-90001 is a JNK (c-Jun N-terminal kinase) inhibitor that can be used as a Phase II clinical candidate to study idiopathic pulmonary fibrosis.
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.
JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.